SCHEMBL6501878

SCHEMBL6501878

OC1CC(CN2CCC(c3ccccc3Cl)CC2)CCc2ccccc21

nearest known ligand 0.75

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 17/20 0.75
KCNH2 Q12809 12/20 0.75
OPRM1 P35372 2/20 0.59
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6504944 0.99 OPRL1 (0.74) OPRL1KCNH2OPRM1HTR7
SCHEMBL6494213 0.87 OPRL1 (0.58) OPRL1KCNH2OPRM1HTR7
SCHEMBL6492306 0.86 OPRL1 (0.77) OPRL1KCNH2OPRM1HTR7
Hydrochloric Acid SCHEMBL6490983 0.86 OPRL1 (0.57) OPRL1KCNH2OPRM1HTR7
SCHEMBL6492309 0.86 OPRL1 (0.77) OPRL1KCNH2OPRM1HTR7
SCHEMBL6491405 0.86 OPRL1 (0.77) OPRL1KCNH2OPRM1HTR7
SCHEMBL6491806 0.85 OPRL1 (0.70) OPRL1KCNH2OPRM1HTR7
SCHEMBL6490537 0.85 OPRL1 (0.70) OPRL1KCNH2OPRM1HTR7
SCHEMBL6492943 0.85 OPRL1 (0.70) OPRL1KCNH2OPRM1HTR7
SCHEMBL6490539 0.85 OPRL1 (0.70) OPRL1KCNH2OPRM1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 US claimed
US-20040024218-A1 Novel compounds SMITHKLINE BEECHAM SPA 2004-02-05 US claimed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 EP claimed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 WO claimed
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 US disclosed
US-6849619-B2 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-01 US disclosed
US-20040024218-A1 Novel compounds SMITHKLINE BEECHAM SPA 2004-02-05 US disclosed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 EP disclosed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024218-A1 Novel compounds OXER1, CLIC1, CCR1 OPRL1 9/4885KCNH2 706/4885OPRM1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.